Frank­furt am Main — Bird & Bird LLP has advi­sed Nort­hern Green Canada Inc. (NGC), the first priva­tely owned licen­sed canna­bis produ­cer from Canada with EU GMP certi­fi­ca­tion, on the forma­tion of Nort­hern Green Global GmbH, based in Unter­schleiss­heim, Germany, and conti­nues to assist Nort­hern Green in its global expan­sion. With the estab­lish­ment of this inter­na­tio­nal phar­maceu­ti­cal company, Nort­hern Green is consis­t­ently pursuing its expan­sion stra­tegy to enable the deli­very of canna­bi­noid medi­ci­nes to global markets.

Nort­hern Green Canada Inc. is a rese­­arch- and deve­­lo­p­­ment-driven manu­fac­tu­rer of high-quality medi­cal canna­bis focu­sed on provi­ding phar­maceu­ti­cal canna­bis products and deve­lo­ping canna­bi­noid formu­la­ti­ons to treat chro­nic dise­a­ses and enhance pati­ents’ quality of life. The company is curr­ently expan­ding its extra­c­tion capa­bi­li­ties to produce oils and is working with renow­ned part­ners on trea­t­­ment-based canna­bis medicines.

Advi­sor NGC: Bird & Bird LLP
Part­ner Dr. Kai Kerger (lead) with Asso­cia­tes Johanna Schind­ler, and Dr. Ann-Kris­­tin Asmuß (all Corpo­rate, Frank­furt), Part­ner Dr. Niels Lutz­höft with Asso­cia­tes Dr. Simon Hembt and Dr. Chris­toph Hendel (all Commercial/ Regu­la­tory, Frank­furt), Part­ner Dr. Barbara Geck with Asso­ciate Carina Seum (both Labor Law, Frankfurt).

Back­ground
Bird & Bird’s cross-juris­­dic­­tio­nal and long-stan­­ding exper­tise places it at the fore­front of advi­sing clients in the medi­cal canna­bis space. Our inter­na­tio­nal canna­bis group advi­ses the market-leading compa­nies in this fast-growing industry.